Search

This paper focuses on the problem of adaptive integral sliding mode control (ISMC) with dissipativity for a type of complex non‐linear system represented by Takagi‐Sugeno (T‐S) fuzzy descriptor models. First, T‐S fuzzy descriptor systems with different derivative matrices are transformed into augmented systems that have the same properties as the original systems, and an integral sliding mode surface function is designed considering the descriptor matrices. Then, based on the dissipativity theory and the non‐parallel distributed compensation (non‐PDC) method, ISMC strategies and dissipativity‐based ISMC strategies are proposed, and the system uncertainties and external disturbances with unknown upper bounds are addressed with an adaptive controller. According to the Lyapunov theory and the dissipativity theory, a fuzzy Lyapunov function is designed, and the obtained criteria are presented in the form of strict linear matrix inequalities (LMIs); this approach guarantees that the closed‐loop system is asymptotically stable and strictly (Q,R,S)−α$(\mathcal{Q},\mathcal{R},\mathcal{S}) - {{\alpha}}$ dissipative. Moreover, the controller gain matrices and Lyapunov matrices are decoupled by introducing the corresponding auxiliary variables and employing Finsler's lemma. Finally, two examples are provided to illustrate the effectiveness and merit of the proposed method. [ABSTRACT FROM AUTHOR]

The national experimental teaching demonstration center of automobile engineering in the university has reformed the existing teaching system, teaching methods and teaching means by improving the training scheme of innovative talents and established the comprehensive experimental course assessment system in the course of developing the training and construction of innovative talents for automobile transportation. New achievements have been made in the training of innovative talents through the measures such as the combination of scientific research projects and teaching contents, the promotion of the integration of competition and training, the exertion of the role of off-campus training bases, etc. [ABSTRACT FROM AUTHOR]

Objective: To analyze the clinical efficacy and toxicity of vitamin support in lung adenocarcinoma patients treated with pemetrexed second-line chemotherapy., Methods: Two hundred and eighty-three patients with stage 3/4 lung adenocarcinoma treated at our hospital from August 2010 to August 2013 were included in this study. The lung adenocarcinomas in all the 283 patients were confirmed by pathology or cytology, all were EGFR-negative, and all patients received pemetrexed second line chemotherapy. The 283 patients were randomly divided into two groups: the improved treatment group (142 cases) and the conventional treatment group (141 cases). The patients of conventional treatment group received 400 µg folic acid per os daily for 7 days before the first dose of pemetrexed, and continued until 21 days after the last dose of pemetrexed. Besides, they received 1000 µg vitamin B12 injection at 7 days before the first dose of pemetrexed, and once per cycle of pemetrexed for 3 cycles after the last dose of pemetrexed. The patients of the improved treatment group took 400 µg folic acid daily per os from the day before the first dose to 21 days after the last dose of pemetrexed. They also received 500 µg vitamin B12 by injection one day before the first dose, and one day before each therapy cycle of pemetrexed therapy., Results: The mean number of cycles of pemetrexed chemotherapy was 4 in both groups. In the 142 patients of improved treatment group, complete response (CR) was observed in two cases, partial remission (PR) in 28, stable disease (SD) in 21, and progressive disease (PD) in 91 cases, with a total effective rate of 21.1%. While in the conventional treatment group, CR was observed in one case, PR in 27 cases, SD in 23 cases, and PD in 90 cases, with a total effective rate of 19.9%. The median progression-free survival (PFS) was 3.8 months in the improved treatment group and 4.2 months in the conventional treatment group (P=0.143). The toxicity of chemotherapy was mild in both groups, with no significant difference between the two groups (P>0.05). The most common side effects of hematological system were leukopenia and neutropenia, and the most common side effects of non-blood system were nausea and vomiting. The most common grade 3-4 toxic reaction in both groups was leukopenia and neutropenia, with no significant difference between the two groups (P>0.05). Multivariate analysis showed that the age of patients was an independent factor of grade 3-4 chemotherapy toxic reaction (P<0.05), while gender, the baseline level of PS score or blood system had no significant effect on the grade 3-4 chemotherapy toxic reaction (P>0.05)., Conclusions: Compared with the conventional treatment scheme, the improved treatment scheme has similar therapeutic effects and could be used more conveniently, while the toxic effects of chemotherapy are not increased at the same time. Our results indicate that pemetrexed-based chemotherapy does not need to delay the chemotherapy because of vitamin support treatment.